MannKindの2025年第4四半期の売上高は前年比45.8%増加し、1億1196万ドルとなりました。これはFuroscixとAfrezzaの好調な販売に支えられていますが、同社は予想を大きく下落させ、株価は52週間ぶりの安値に下落しました。 MannKind's Q4 2025 revenue rose 45.8% year-over-year to $111.96 million, driven by strong sales of Furoscix and Afrezza, but the company posted a larger-than-expected loss, causing its stock to fall to a 52-week low.

MannKindは,Furoscix,Afrezza,およびロイヤリティの強い売上高により,2025年第4四半期売上高が111.96億米ドル,前年比45.8%増加し,推定99.85億米ドルを超えたが,四半期損失は1株当たり0.05米ドルで,予想損失0.01米ドルを逃した. MannKind reported Q4 2025 revenue of $111.96 million, a 45.8% year-over-year increase and above the $99.85 million estimate, driven by strong sales of Furoscix, Afrezza, and royalties, but posted a quarterly loss of $0.05 per share, missing the expected loss of $0.01. 株価は52週間の低水準に下がった 収益の成長にもかかわらず アナリストは混合評価と価格目標の低下を提案し 内部情報販売とマイナス技術指標は短期的な弱さを示した. The stock fell to a 52-week low despite revenue growth, with analysts offering mixed ratings and lowered price targets, while insider selling and bearish technical indicators signaled near-term weakness.